Abstract
Previous studies have shown frequent allelic loss on chromosome 13 in esophageal squamous cell carcinoma (ESCC). We assessed the frequency of allelic loss on chromosome 13q14 and mutations of deleted in cancer 1 (DICE1) (also found on 13q14) in ESCC patients to determine if this candidate tumor suppressor gene has a role in the development of ESCC, and whether this gene was an inactivation target for allelic loss on chromosome 13q14. Initially, we examined allelic loss at five markers flanking DICE1 in 56 ESCC patients from Shanxi Province, China, and then examined the entire coding sequence of this gene for mutations using polymerase chain reaction–single-strand confirmation polymorphism (PCR–SSCP) analysis and DNA sequencing. Subsequently, we extended our evaluation to an additional 80 ESCC patients and 232 healthy individuals to confirm the germline variant found in the initial 56 ESCC patients. The frequencies of allelic loss were 71, 58, and 75% for D13S325, D13S757, and D13S887, respectively, in the initial 56 ESCC patients studied. Overall, 73% of informative patients had loss of heterozygosity (LOH) for at least one of these three markers. Somatic mutations were identified in three patients (3/56, 5%), and one novel polymorphism was identified in 3% of ESCC patients (4/136) and 3% of healthy individuals (6/232). We conclude that DICE1 mutations occur in ESCC but are infrequent. The candidate tumor suppressor gene corresponding to the frequent allelic loss on chromosome 13q14 in ESCC remains unknown.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
Abbreviations
- ESCC:
-
esophageal squamous cell carcinoma
- SSCP:
-
single-strand confirmation polymorphism
- PCR:
-
polymerase chain reaction
- LOH:
-
loss of heterozygosity
References
Boynton RF, Huang Y, Blount PL, Reid BJ, Raskind WH, Haggitt RC, Newkirk C, Resau JH, Yin J, McDaniel T and Meltzer SJ. (1991). Cancer Res., 51, 5766–5769.
Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA and Liotta LA. (1996). Laser capture microdissection. Science, 274, 998–1001.
Eìrìksdottir G, Johannesdottir G, Ingvarsson S, Bjornsdottir IB, Jonasson JG, Agnarsson BA, Hallgrimsson J, Gudmundsson J, Egilsson V, Sigurdsson H and Barkardottir RB. (1998). Eur. J. Cancer, 34, 2076–2081.
Hu N, Dawsey SM, Wu M, Bonney GE, He LJ, Han XY, Fu M and Taylor PR. (1992). Int. J. Epidemol., 21, 877–881.
Hu N, Huang J, Emmert-Buck MR, Tang ZZ, Roth MJ, Wang CY, Dawsey SM, Li G, Li WJ, Wang QH, Han XY, Ding T, Giffen C, Goldstein AM and Taylor PR. (2001). Clin. Cancer Res., 7, 883–891.
Hu N, Li G, Li WJ, Wang CY, Goldstein AM, Tang ZZ, Roth MJ, Dawsey SM, Huang J, Wang QH, Ding T, Giffen C, Taylor PR and Emmert-Buck MR. (2002). Clin. Cancer Res., 8, 1121–1126.
Hu N, Roth MJ, Emmert-Buck MR, Tang ZZ, Polymeropolous M, Wang QH, Goldstein AM, Han XY, Dawsey SM, Ding T, Giffen C and Taylor PR. (1999). Clin. Cancer Res., 5, 3476–3482.
Hu N, Roth MJ, Polymeropolous M, Tang ZZ, Emmert-Buck MR, Wang QH, Goldstein AM, Feng SS, Dawsey SM, Ding T, Zhuang ZP, Han XY, Reid T, Giffen C and Taylor PR. (2000). Genes Chromosomes Cancer, 27, 217–228.
Huang Y, Boynton RF, Blount PL, Silberstein RJ, Yin J, Tong Y, McDaniel TK, Newkirk C, Resau JH, Sridhara R, Reid BJ and Meltzer SJ. (1992). Cancer Res., 52, 6525–6530.
Huang J, Hu N, Goldstein AM, Emmert-Buck MR, Tang ZZ, Roth MJ, Wang QH, Dawsey SM, Han XY, Ding T, Li G, Giffen C and Taylor PR. (2000). Carcinogenesis, 21, 2019–2026.
Hyytinen ER, Frierson JR HF, Boyd JC, Chung LWK and Dong JT. (1999). Genes Chromosomes Cancer, 25, 108–114.
Kuroki T, Fujiwara Y, Nakamori S, Imaoka S, Kanematsu T and Nakamura Y. (1995). Br. J. Cancer, 72, 383–385.
Lee WH, Bookstein R, Hong F, Young LJ, Shew EY and Lee EY. (1987). Science, 235, 1394–1399.
Li G, Hu N, Goldstein AM, Tang ZZ, Roth MJ, Wang QH, Dawsey SM, Han XY, Ding T, Huang J, Giffen C, Taylor PR and Emmert-Buck MR. (2001). Genes Chromosomes & Cancer, 31, 390–397.
MacGee TL, Yandell DW and Dryjia TP. (1989). Gene, 80, 119–128.
Maesawa C, Tamura G, Suzuki Y, Ogasawara S, Ishida K, Satio K and Satodate R. (1994). Int. J. Cancer, 57, 21–25.
Montesano R, Hollstein M and Hainaut P. (1996). Int. J. Cancer, 69, 225–235.
Wieland I, Arden KC, Michels D, Klein-Hitpass L, Bohm M, Viars CS and Weidle UH. (1999). Oncogene, 18, 4530–4537.
Wieland I, Ropke A, Stumm M, Sell C, Weidle UH and Wieacker PF. (2001). Oncol. Res., 12, 491–500.
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C and Micklem G. (1995). Nature, 378, 789–792.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, WJ., Hu, N., Su, H. et al. Allelic loss on chromosome 13q14 and mutation in deleted in cancer 1 gene in esophageal squamous cell carcinoma. Oncogene 22, 314–318 (2003). https://doi.org/10.1038/sj.onc.1206098
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206098
Keywords
This article is cited by
-
Decoding the prognostic significance of integrator complex subunit 9 (INTS9) in glioma: links to TP53 mutations, E2F signaling, and inflammatory microenvironments
Cancer Cell International (2023)
-
RNA processing errors triggered by cadmium and integrator complex disruption are signals for environmental stress
BMC Biology (2019)
-
Integrator complex subunit 6 (INTS6) inhibits hepatocellular carcinoma growth by Wnt pathway and serve as a prognostic marker
BMC Cancer (2017)
-
Promoter CpG hypermethylation and downregulation of DICE1 expression in prostate cancer
Oncogene (2005)